GlassScriptPhysician profile
Melvin Belafsky
NPI 1831114271
$2,625.17
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $306 · 2021: $777 · 2022: $887 · 2023: $23.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $371.85 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $338.03 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $251.96 | 2019-2023 | Austedo |
| Mdd US Operations, LLC | $243.54 | 2019-2022 | |
| Sk Life Science, INC. | $208.96 | 2020-2022 | |
| Amgen INC. | $193.97 | 2019-2021 | |
| Ucb, INC. | $179.64 | 2019-2022 | |
| Abbvie INC. | $136.50 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $117.32 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $70.91 | 2020-2021 | |
| Genzyme Corporation | $57.41 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $48.74 | 2022 | |
| Grifols USA, LLC | $47.39 | 2020-2021 | |
| Livanova USA, INC. | $42.42 | 2020-2022 | |
| Akcea Therapeutics, INC. | $41.11 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $32.72 | 2019 | |
| Travere Therapeutics, INC. | $32.51 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.47 | 2021 | |
| Acadia Pharmaceuticals INC | $23.93 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.48 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.63 | 2020 | |
| Shire North American Group INC | $21.19 | 2019 | |
| Avanir Pharmaceuticals, INC. | $20.36 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.45 | 2021 | |
| Boston Scientific Corporation | $14.14 | 2021 | |
| Celgene Corporation | $12.04 | 2021 | |
| Eisai INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Belafsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.